ABCB1 and ovarian carcinoma: Notably, recurrent ovarian cancers demonstrate significantly increased MDR1 compared to primary ovarian cancers, with the recurrent patients receiving platinum-taxane therapy as a standard of care after the diagnosis of their primary cancer [10].